Journal article
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials
Poornima Saha, Meredith M Regan, Olivia Pagani, Prudence A Francis, Barbara A Walley, Karin Ribi, Jurg Bernhard, Weixiu Luo, Henry L Gomez, Harold J Burstein, Vani Parmar, Roberto Torres, Josephine Stewart, Meritxell Bellet, Antonia Perello, Faysal Dane, Antonio Moreira, Daniel Vorobiof, Michelle Nottage, Karen N Price Show all
JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2017
Abstract
Purpose To describe benefits and toxicities of adjuvant endocrine therapies in women younger than 35 years with breast cancer (n = 582) enrolled in the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT). Methods In SOFT, women still premenopausal after surgery with or without chemotherapy were randomly assigned to tamoxifen alone, tamoxifen plus ovarian function suppression (OFS), or exemestane plus OFS. In TEXT, all received OFS with or without concomitant chemotherapy and were randomly assigned to exemestane plus OFS or tamoxifen plus OFS. We summarize treatment efficacy, quality of life, and adherence of the cohort of women younger than 35 years in SOFT..
View full abstractGrants
Awarded by US NCI
Awarded by National Health and Medical Research Council
Awarded by National Institutes of Health ( NIH)
Awarded by NIH
Awarded by Canadian Cancer Society Research Institute
Awarded by Cancer Research UK
Awarded by NATIONAL CANCER INSTITUTE
Funding Acknowledgements
TEXTand SOFT received financial support for trial conduct from Pfizer, the International Breast Cancer Study Group (IBCSG), and the US National Cancer Institute (NCI). Pfizer and Ipsen provided drug supply. The pharmaceutical companies have no role in the reporting or interpretation of the trials, other than a minority representation on the Steering Committee. Support for the coordinating group, IBCSG: Frontier Science and Technology Research Foundation, Swiss Group for Clinical Cancer Research, Cancer Research Switzerland/Oncosuisse, the Foundation for Clinical Cancer Research of Eastern Switzerland, and the US NCI Grant No. CA75362.Grant support of cooperative groups: Australia and New Zealand Breast Cancer Trials Group supported by National Health and Medical Research Council Grants No. 351161, 510788, and 1105058; Southwest Oncology Group supported by National Institutes of Health ( NIH) Grant No. CA32102; Alliance for Clinical Trials in Oncology supported by NIH Grant No. CA180821; Eastern Cooperative Oncology Group-American College of Radiology Imaging Network supported by NIH Grants No. CA21115 and CA16116; National Surgical Adjuvant Breast and Bowel Project/NRG Oncology supported by NIH Grants No. U10-CA-12027, U10-CA-69651, U10-CA37377, and U10-CA-69974; National Cancer Institute of Canada Clinical Trials Group supported by NIH Grant No. CA077202 and Canadian Cancer Society Research Institute Grants No. 015469 and 021039; Institute of Cancer Research Clinical Trials and Statistics Unit on behalf of the National Cancer Research Institute Breast Clinical Studies Group United Kingdom supported by Cancer Research UK Grants No. CRUKE/03/022, CRUKE/03/023, and A15955; National Institute for Health Research Royal Marsden/Institute of Cancer Research Biomedical Research Centre; and National Institute for Health Research Cambridge Biomedical Research Centre.